Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Leukemia vaccines.

Literature DB >> 11296128

Leukemia vaccines.

Abstract

Leukemia is susceptible to immune-mediated therapies such as allogeneic stem-cell transplantation, donor lymphocyte infusion, and interferon. The clinical effectiveness of these immune-based modalities has encouraged interest in vaccine therapies for leukemia. Substantial progress has recently been made in basic immunology, allowing scientifically based vaccination strategies to be developed. The discovery of leukemia- specific and leukemia-associated antigens will allow antigen-specific therapeutic strategies to be developed. Vaccination with genetically modified leukemia cells and the use of dendritic cells in various vaccination approaches are all promising avenues of study for development of effective leukemia vaccines.

Entities: Disease Species

Mesh：

Substances：

Year: 2001 PMID： 11296128 DOI： 10.1007/s11912-001-0050-3

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

50 in total

Review 1. Cancer vaccines.

Authors: D M Pardoll
Journal: Nat Med Date: 1998-05 Impact factor: 53.440

2. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.

Authors: J H Falkenburg; A R Wafelman; P Joosten; W M Smit; C A van Bergen; R Bongaerts; E Lurvink; M van der Hoorn; P Kluck; J E Landegent; H C Kluin-Nelemans; W E Fibbe; R Willemze
Journal: Blood Date: 1999-08-15 Impact factor: 22.113

3. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors: R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544

4. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.

Authors: K Dunussi-Joannopoulos; G Dranoff; H J Weinstein; J L Ferrara; B E Bierer; J M Croop
Journal: Blood Date: 1998-01-01 Impact factor: 22.113

5. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen.

Authors: E H Warren; M A Gavin; E Simpson; P Chandler; D C Page; C Disteche; K A Stankey; P D Greenberg; S R Riddell
Journal: J Immunol Date: 2000-03-01 Impact factor: 5.422

6. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.

Authors: A Choudhury; J L Gajewski; J C Liang; U Popat; D F Claxton; K O Kliche; M Andreeff; R E Champlin
Journal: Blood Date: 1997-02-15 Impact factor: 22.113

7. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

Authors: R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff
Journal: Proc Natl Acad Sci U S A Date: 1998-10-27 Impact factor: 11.205

Review 1. New vaccine development.

Authors: Gregory A Poland; Dennis Murray; Ruben Bonilla-Guerrero
Journal: BMJ Date: 2002-06-01

1 in total